2021

Nov 22

Announced the approval of Taiwan's ANDA (Abbreviated New Drug Application) for our company's product, 50 mg Caspofungin Acetate for Injection.

Oct 5

Announced the approval of the U.S. ANDA (Abbreviated New Drug Application) for our company's Caspofungin Acetate for Injection in both 50 mg and 70 mg strengths.

Jun 23

Our company has been listed on the emerging stock market.

Jun 11

Announced the unblinding and analysis results of the interim data from the Phase III human clinical trials of our erythropoietin product UB-851.